tiprankstipranks
Trending News
More News >
Neuren Pharmaceuticals Limited (AU:NEU)
ASX:NEU
Australian Market

Neuren Pharmaceuticals Limited (NEU) Ratios

Compare
204 Followers

Neuren Pharmaceuticals Limited Ratios

AU:NEU's free cash flow for Q2 2024 was AU$0.26. For the 2024 fiscal year, AU:NEU's free cash flow was decreased by AU$ and operating cash flow was AU$0.17. See a summary of the company’s cash flow.
Ratios
TTM
Dec 23Dec 22Dec 21Dec 20
Liquidity Ratios
Current Ratio
5.78 25.77 49.87 33.12 25.75
Quick Ratio
5.78 25.77 49.87 34.13 26.72
Cash Ratio
0.40 23.95 45.81 32.12 24.77
Solvency Ratio
3.67 0.12 -9.70 -12.20 -19.34
Operating Cash Flow Ratio
4.32 2.14 -12.42 -10.73 -20.96
Short-Term Operating Cash Flow Coverage
0.00 0.00 0.00 0.00 0.00
Net Current Asset Value
AU$ ―AU$ ―AU$ ―AU$ ―AU$ ―
Leverage Ratios
Debt-to-Assets Ratio
0.00 0.00 0.00 0.00 0.00
Debt-to-Equity Ratio
0.00 0.00 0.00 0.00 0.00
Debt-to-Capital Ratio
0.00 0.00 0.00 0.00 0.00
Long-Term Debt-to-Capital Ratio
0.00 0.00 0.00 0.00 0.00
Financial Leverage Ratio
1.21 1.04 1.02 1.03 1.04
Debt Service Coverage Ratio
0.00 0.00 0.00 0.00 0.00
Interest Coverage Ratio
0.00 0.00 0.00 0.00 0.00
Debt to Market Cap
0.00 0.00 0.00 0.00 0.00
Interest Debt Per Share
0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA
Profitability Margins
Gross Profit Margin
88.47%99.93%99.75%99.16%99.19%
EBIT Margin
85.89%-11.04%-343.79%-1382.15%-2285.05%
EBITDA Margin
85.92%-10.90%-257.27%-1227.75%-2236.77%
Operating Profit Margin
74.37%-10.97%-357.52%-1328.59%-2337.58%
Pretax Profit Margin
88.45%-4.67%-343.79%-1382.15%-2285.05%
Net Profit Margin
67.73%1.26%-243.79%-1282.15%-2185.05%
Continuous Operations Profit Margin
67.73%1.26%-243.79%-1282.15%-2185.05%
Net Income Per EBT
76.57%-27.06%70.91%92.76%95.62%
EBT Per EBIT
118.93%42.61%96.16%104.03%97.75%
Return on Assets (ROA)
Return on Equity (ROE)
Return on Capital Employed (ROCE)
Return on Invested Capital (ROIC)
Return on Tangible Assets
Earnings Yield
Efficiency Ratios
Receivables Turnover
16.09 13.36 2.25 0.95 0.90
Payables Turnover
39.63 0.04 0.03 0.04 0.01
Inventory Turnover
0.00 0.00 8.00K >-0.01 >-0.01
Fixed Asset Turnover
5.39K 693.00 266.42 71.70 49.50
Asset Turnover
0.94 0.34 0.08 0.03 0.03
Working Capital Turnover Ratio
Cash Conversion Cycle
Days of Sales Outstanding
Days of Inventory Outstanding
Days of Payables Outstanding
Operating Cycle
Cash Flow Ratios
Operating Cash Flow Per Share
1.46 0.03 -0.08 -0.08 -0.12
Free Cash Flow Per Share
1.45 0.03 -0.08 -0.08 -0.12
CapEx Per Share
<0.01 <0.01 <0.01 <0.01 <0.01
Free Cash Flow to Operating Cash Flow
1.00 0.99 1.00 1.00 1.00
Dividend Paid and CapEx Coverage Ratio
4.62K 189.42 -997.00 -1.35K -976.58
Capital Expenditure Coverage Ratio
4.62K 189.42 -997.00 -1.35K -976.58
Operating Cash Flow Coverage Ratio
Operating Cash Flow to Sales Ratio
Free Cash Flow Yield
Valuation Ratios
Price-to-Earnings (P/E) Ratio
20.08 5.44K -56.97 -15.02 -22.97
Price-to-Sales (P/S) Ratio
13.60 68.81 138.88 192.61 501.85
Price-to-Book (P/B) Ratio
15.37 24.08 11.31 5.71 17.94
Price-to-Free Cash Flow (P/FCF) Ratio
17.06 279.73 -44.49 -17.08 -21.18
Price-to-Operating Cash Flow Ratio
17.05 278.25 -44.53 -17.10 -21.20
Price-to-Earnings Growth (PEG) Ratio
<0.01 -53.22 2.48 0.69 0.05
Price-to-Fair Value
15.37 24.08 11.31 5.71 17.94
Enterprise Value Multiple
15.74 -606.08 -49.51 -12.94 -21.19
EV to EBITDA
EV to Sales
EV to Free Cash Flow
EV to Operating Cash Flow
Tangible Book Value Per Share
1.61 0.33 0.33 0.23 0.14
Shareholders’ Equity Per Share
1.61 0.33 0.33 0.23 0.14
Tax and Other Ratios
Effective Tax Rate
0.23 1.27 0.29 0.07 0.04
Revenue Per Share
1.83 0.12 0.03 <0.01 <0.01
Net Income Per Share
1.24 <0.01 -0.07 -0.09 -0.11
Tax Burden
Interest Burden
Research & Development to Revenue
SG&A to Revenue
Stock-Based Compensation to Revenue
Income Quality
Currency in AUD
What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis